← Back to Search

Electrical Therapy

TTFields for Brain Cancer

N/A
Recruiting
Led By Suyash Mohan, MD, PDCC
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult population ≥ 22 years
Histologically confirmed diagnosis of GBM or molecular GBM according to c-IMPACT NOW criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion and clinical follow ups for up to 5 years
Awards & highlights

Study Summary

This trialis testing a novel electrical therapy to treat brain tumors, using MRI to find where to direct the dose, to maximize effectiveness and improve survival & quality of life.

Who is the study for?
This trial is for adults over 22 with a confirmed diagnosis of Glioblastoma (GBM) who've had surgery and radiation therapy. They must have good blood, liver, and kidney function and be willing to receive TTFields treatment. It's not for those with GBM below the cerebellum, pregnant women, people with certain medical devices or skull defects, or sensitivity to conductive hydrogels.Check my eligibility
What is being tested?
The study tests if an advanced MRI technique called 'whole brain spectroscopy' can better guide the placement of TTFields therapy compared to standard mapping. This could potentially improve survival rates and quality of life by more effectively targeting tumor cells in GBM patients.See study design
What are the potential side effects?
While specific side effects are not listed for this trial, TTFields therapy may cause skin irritation under the device electrodes, headaches, malaise or muscle twitching. The precise side effects will depend on individual patient responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 22 years old or older.
Select...
My diagnosis of brain cancer is confirmed by lab tests.
Select...
I am willing to undergo TTFields therapy.
Select...
My cancer has specific genetic features (MGMT or IDH).
Select...
I've had surgery to remove as much of the tumor as safely possible, followed by a specific course of radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion and clinical follow ups for up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion and clinical follow ups for up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to Progression
Secondary outcome measures
Overall Survival

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Advanced MR Imaging Array Mapping LayoutExperimental Treatment1 Intervention
Participants in this study arm will receive Optune array layout mapping created from advanced MR imaging sequences obtained through trial enrollment.
Group II: Conventional Array Mapping LayoutActive Control1 Intervention
Participants in this study arm will still receive Optune array layout mapping based on standard MR imaging sequences.

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
104,940 Total Patients Enrolled
7 Trials studying Glioblastoma
120 Patients Enrolled for Glioblastoma
Abramson Cancer Center at Penn MedicineLead Sponsor
385 Previous Clinical Trials
144,746 Total Patients Enrolled
7 Trials studying Glioblastoma
120 Patients Enrolled for Glioblastoma
NovoCure Ltd.Industry Sponsor
56 Previous Clinical Trials
4,478 Total Patients Enrolled
28 Trials studying Glioblastoma
2,580 Patients Enrolled for Glioblastoma

Media Library

WBSI Guided Personalized Delivery of TTFields (Electrical Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05086497 — N/A
Glioblastoma Research Study Groups: Conventional Array Mapping Layout, Advanced MR Imaging Array Mapping Layout
Glioblastoma Clinical Trial 2023: WBSI Guided Personalized Delivery of TTFields Highlights & Side Effects. Trial Name: NCT05086497 — N/A
WBSI Guided Personalized Delivery of TTFields (Electrical Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05086497 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment currently accept contributions from volunteers?

"According to the information on clinicialtrials.gov this investigation is still recruiting participants. The trial was initially posted on 15th of January, 2023 and has been revised most recently 19th of January, 2023."

Answered by AI

How many participants are enrolled in this research project?

"Affirmative. Clinicaltrials.gov confirms that this research project, which was first advertised on January 15th 2023, is actively seeking volunteers for enrollment. 155 individuals need to be conscripted from two medical centres."

Answered by AI
~102 spots leftby Jun 2026